BRAF and non-small cell lung carcinoma: Mutations in the BRAF gene, which occur in 2%-5% of NSCLC patients, have been identified as a therapeutic target for some time.2, 3, 4, 5BRAF encodes for the protein serine/threonine protein kinase BRAF, which is involved in the regulation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signalling pathway and affects cell division and differentiation.